AU641363B2 - Contrast preparation consisting of cavitate- or clathrate- forming host/guest complexes - Google Patents
Contrast preparation consisting of cavitate- or clathrate- forming host/guest complexes Download PDFInfo
- Publication number
- AU641363B2 AU641363B2 AU40651/89A AU4065189A AU641363B2 AU 641363 B2 AU641363 B2 AU 641363B2 AU 40651/89 A AU40651/89 A AU 40651/89A AU 4065189 A AU4065189 A AU 4065189A AU 641363 B2 AU641363 B2 AU 641363B2
- Authority
- AU
- Australia
- Prior art keywords
- derivatives
- guest
- hydrogen
- solution
- host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002360 preparation method Methods 0.000 title claims description 24
- 238000011835 investigation Methods 0.000 claims abstract description 15
- 239000002872 contrast media Substances 0.000 claims abstract description 14
- 229940039231 contrast media Drugs 0.000 claims abstract 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 47
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 27
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 24
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 18
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims description 18
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 18
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 16
- -1 hexakis (phenylthio) Chemical class 0.000 claims description 14
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 claims description 14
- 239000004202 carbamide Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229910052724 xenon Inorganic materials 0.000 claims description 13
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 13
- 229910052786 argon Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 11
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- CRSOQBOWXPBRES-UHFFFAOYSA-N neopentane Chemical compound CC(C)(C)C CRSOQBOWXPBRES-UHFFFAOYSA-N 0.000 claims description 10
- 239000001273 butane Substances 0.000 claims description 9
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 9
- 239000001294 propane Substances 0.000 claims description 9
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 8
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 8
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 239000001569 carbon dioxide Substances 0.000 claims description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 8
- ZIKHLMVJGCYVAC-UHFFFAOYSA-N tri-o-thymotide Chemical compound O1C(=O)C2=C(C)C=CC(C(C)C)=C2OC(=O)C2=C(C)C=CC(C(C)C)=C2OC(=O)C2=C1C(C(C)C)=CC=C2C ZIKHLMVJGCYVAC-UHFFFAOYSA-N 0.000 claims description 8
- 229910001868 water Inorganic materials 0.000 claims description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 7
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 7
- 239000001282 iso-butane Substances 0.000 claims description 7
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 claims description 7
- 229960000909 sulfur hexafluoride Drugs 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000005864 Sulphur Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 239000011261 inert gas Substances 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- YECHEDVCXXVLIY-UHFFFAOYSA-N cyclotriveratrylene Chemical group C1C2=CC(OC)=C(OC)C=C2CC2=CC(OC)=C(OC)C=C2CC2=C1C=C(OC)C(OC)=C2 YECHEDVCXXVLIY-UHFFFAOYSA-N 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 229940102396 methyl bromide Drugs 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 3
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 claims description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- RBFQJDQYXXHULB-UHFFFAOYSA-N arsane Chemical compound [AsH3] RBFQJDQYXXHULB-UHFFFAOYSA-N 0.000 claims description 3
- 229910000070 arsenic hydride Inorganic materials 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 3
- HOXINJBQVZWYGZ-UHFFFAOYSA-N fenbutatin oxide Chemical compound C=1C=CC=CC=1C(C)(C)C[Sn](O[Sn](CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C=1C=CC=CC=1)(CC(C)(C)C=1C=CC=CC=1)CC(C)(C)C1=CC=CC=C1 HOXINJBQVZWYGZ-UHFFFAOYSA-N 0.000 claims description 3
- 150000002206 flavan-3-ols Chemical class 0.000 claims description 3
- 235000011987 flavanols Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 150000008282 halocarbons Chemical class 0.000 claims description 3
- 239000001307 helium Substances 0.000 claims description 3
- 229910052734 helium Inorganic materials 0.000 claims description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 3
- 229930195733 hydrocarbon Natural products 0.000 claims description 3
- 150000002430 hydrocarbons Chemical class 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229910052743 krypton Inorganic materials 0.000 claims description 3
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052754 neon Inorganic materials 0.000 claims description 3
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 229910052704 radon Inorganic materials 0.000 claims description 3
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims description 3
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 claims description 3
- BLIQUJLAJXRXSG-UHFFFAOYSA-N 1-benzyl-3-(trifluoromethyl)pyrrolidin-1-ium-3-carboxylate Chemical compound C1C(C(=O)O)(C(F)(F)F)CCN1CC1=CC=CC=C1 BLIQUJLAJXRXSG-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- BMYPQOLESFVQPA-UHFFFAOYSA-N O=[Xe]=O Chemical compound O=[Xe]=O BMYPQOLESFVQPA-UHFFFAOYSA-N 0.000 claims description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910002090 carbon oxide Inorganic materials 0.000 claims description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims description 2
- 150000001843 chromanes Chemical class 0.000 claims description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
- 229960003964 deoxycholic acid Drugs 0.000 claims description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 229910000043 hydrogen iodide Inorganic materials 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 150000002924 oxiranes Chemical class 0.000 claims description 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 2
- SANRKQGLYCLAFE-UHFFFAOYSA-H uranium hexafluoride Chemical compound F[U](F)(F)(F)(F)F SANRKQGLYCLAFE-UHFFFAOYSA-H 0.000 claims description 2
- ARUUTJKURHLAMI-UHFFFAOYSA-N xenon hexafluoride Chemical compound F[Xe](F)(F)(F)(F)F ARUUTJKURHLAMI-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 13
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 239000012530 fluid Substances 0.000 claims 6
- 229910018503 SF6 Inorganic materials 0.000 claims 4
- 229960004337 hydroquinone Drugs 0.000 claims 3
- 239000001272 nitrous oxide Substances 0.000 claims 3
- 108010010803 Gelatin Proteins 0.000 claims 2
- 229910052770 Uranium Inorganic materials 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 229940117927 ethylene oxide Drugs 0.000 claims 2
- 239000008273 gelatin Substances 0.000 claims 2
- 235000011852 gelatine desserts Nutrition 0.000 claims 2
- 239000008223 sterile water Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- RPSSQXXJRBEGEE-UHFFFAOYSA-N xenon tetrafluoride Chemical compound F[Xe](F)(F)F RPSSQXXJRBEGEE-UHFFFAOYSA-N 0.000 claims 2
- BDLNCFCZHNKBGI-UHFFFAOYSA-N 1-nitro-4-(4-nitrophenyl)benzene Chemical group C1=CC([N+](=O)[O-])=CC=C1C1=CC=C([N+]([O-])=O)C=C1 BDLNCFCZHNKBGI-UHFFFAOYSA-N 0.000 claims 1
- 241000518994 Conta Species 0.000 claims 1
- 235000009245 Elaeagnus multiflora Nutrition 0.000 claims 1
- 240000000298 Elaeagnus multiflora Species 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 101100238304 Mus musculus Morc1 gene Proteins 0.000 claims 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 claims 1
- 229940099352 cholate Drugs 0.000 claims 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 150000002978 peroxides Chemical class 0.000 claims 1
- 150000002989 phenols Chemical class 0.000 claims 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 claims 1
- 239000013078 crystal Substances 0.000 description 58
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 38
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 22
- 238000001035 drying Methods 0.000 description 19
- 239000005968 1-Decanol Substances 0.000 description 11
- 239000007789 gas Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- KXYDGGNWZUHESZ-UHFFFAOYSA-N 4-(2,2,4-trimethyl-3h-chromen-4-yl)phenol Chemical compound C12=CC=CC=C2OC(C)(C)CC1(C)C1=CC=C(O)C=C1 KXYDGGNWZUHESZ-UHFFFAOYSA-N 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 238000010586 diagram Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000006163 transport media Substances 0.000 description 2
- IZRWZLBCZMYWIG-UHFFFAOYSA-N 1,2-dinitro-3-phenylbenzene Chemical group [O-][N+](=O)C1=CC=CC(C=2C=CC=CC=2)=C1[N+]([O-])=O IZRWZLBCZMYWIG-UHFFFAOYSA-N 0.000 description 1
- RZWKXCCZVCZJOU-UHFFFAOYSA-N 2,2,4-trimethyl-3,4-dihydrochromene Chemical compound C1=CC=C2C(C)CC(C)(C)OC2=C1 RZWKXCCZVCZJOU-UHFFFAOYSA-N 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- ICEQLCZWZXUUIJ-UHFFFAOYSA-N decan-3-ol Chemical compound CCCCCCCC(O)CC ICEQLCZWZXUUIJ-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 150000002211 flavins Chemical class 0.000 description 1
- 210000001214 frontal sinus Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- PCILLCXFKWDRMK-UHFFFAOYSA-N naphthalene-1,4-diol Chemical compound C1=CC=C2C(O)=CC=C(O)C2=C1 PCILLCXFKWDRMK-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000004291 sulphur dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/189—Host-guest complexes, e.g. cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/228—Host-guest complexes, clathrates, chelates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3828905A DE3828905A1 (de) | 1988-08-23 | 1988-08-23 | Mittel bestehend aus cavitate oder clathrate bildenden wirt/gast-komplexen als kontrastmittel |
| DE3828905 | 1988-08-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4065189A AU4065189A (en) | 1990-03-23 |
| AU641363B2 true AU641363B2 (en) | 1993-09-23 |
Family
ID=6361599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU40651/89A Ceased AU641363B2 (en) | 1988-08-23 | 1989-08-18 | Contrast preparation consisting of cavitate- or clathrate- forming host/guest complexes |
Country Status (12)
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770222A (en) | 1989-12-22 | 1998-06-23 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
| US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
| US5853752A (en) | 1989-12-22 | 1998-12-29 | Imarx Pharmaceutical Corp. | Methods of preparing gas and gaseous precursor-filled microspheres |
| US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
| US5935553A (en) | 1989-12-22 | 1999-08-10 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US5985246A (en) | 1989-12-22 | 1999-11-16 | Imarx Pharmaceutical Corp. | Contrast agents for ultrasonic imaging and methods for preparing the same |
| US6028066A (en) | 1997-05-06 | 2000-02-22 | Imarx Pharmaceutical Corp. | Prodrugs comprising fluorinated amphiphiles |
| US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US6117414A (en) | 1991-04-05 | 2000-09-12 | Imarx Pharmaceutical Corp. | Method of computed tomography using fluorinated gas-filled lipid microspheres as contract agents |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
| US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
| US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
| US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
| US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
| US6443898B1 (en) | 1989-12-22 | 2002-09-03 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems |
| US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
| US6528039B2 (en) | 1991-04-05 | 2003-03-04 | Bristol-Myers Squibb Medical Imaging, Inc. | Low density microspheres and their use as contrast agents for computed tomography and in other applications |
| US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
| US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| US6638767B2 (en) | 1996-05-01 | 2003-10-28 | Imarx Pharmaceutical Corporation | Methods for delivering compounds into a cell |
| US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| US7078015B2 (en) | 1989-12-22 | 2006-07-18 | Imarx Therapeutics, Inc. | Ultrasound imaging and treatment |
| US7083572B2 (en) | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| US7452551B1 (en) | 2000-10-30 | 2008-11-18 | Imarx Therapeutics, Inc. | Targeted compositions for diagnostic and therapeutic use |
| US8084056B2 (en) | 1998-01-14 | 2011-12-27 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN172208B (enrdf_load_html_response) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
| US5445813A (en) | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
| US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| ATE151993T1 (de) * | 1991-07-05 | 1997-05-15 | Nycomed Imaging As | Verbesserungen an kontrastmitteln |
| US6723303B1 (en) | 1991-09-17 | 2004-04-20 | Amersham Health, As | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
| MX9205298A (es) | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
| US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
| WO1993005819A1 (en) * | 1991-09-17 | 1993-04-01 | Sonus Pharmaceuticals, Inc | Gaseous ultrasound contrast media and method for selecting gases for use as ultrasound contrast media |
| IL104084A (en) * | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them |
| US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
| CA2154590C (en) * | 1993-01-25 | 2001-06-12 | Steven C. Quay | Phase shift colloids as ultrasound contrast agents |
| IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Colloids with phase difference as contrast ultrasound agents |
| CN1061893C (zh) * | 1993-03-08 | 2001-02-14 | 柯铭清 | 声学造影剂 |
| US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
| DK0711179T3 (da) | 1993-07-30 | 2005-02-14 | Imcor Pharmaceutical Co | Stabiliserede sammensætninger med mikrobobler til ultralyd |
| US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
| PL182223B1 (pl) | 1993-12-15 | 2001-11-30 | Bracco Research Sa | Biokompatybilna faza rozproszona do otrzymywania srodka kontrastowego do badan ultradzwiekowych, srodek kontrastowy do badan ultradzwiekowych, suchy preparat srodka kontrastowego oraz dwuskladnikowy zestaw do otrzymywania srodka kontrastowego do badan ultradzwiekowych PL PL PL |
| US5545396A (en) * | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
| US5622687A (en) * | 1994-11-15 | 1997-04-22 | Molecular Biosystems, Inc. | Calixarene conjugates useful as MRI and CT diagnostic imaging agents |
| EP0766968B1 (en) * | 1995-10-06 | 2001-01-17 | Nihon Medi-Physics Co., Ltd. | Diagnostic imaging agent |
| DE19543077C2 (de) * | 1995-11-13 | 1997-10-16 | Schering Ag | Verwendung von gashaltigen Metallkomplexen als Ultraschallkontrastmittel |
| IL126073A (en) * | 1996-03-05 | 2002-02-10 | Acusphere Inc | Microencapsulated fluorinated gases for use as imaging agents |
| US5611344A (en) * | 1996-03-05 | 1997-03-18 | Acusphere, Inc. | Microencapsulated fluorinated gases for use as imaging agents |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US6284222B1 (en) | 1998-11-03 | 2001-09-04 | Medi--Physics, Inc. | Hyperpolarized helium-3 microbubble gas entrapment methods |
| DE19851605A1 (de) * | 1998-11-09 | 2000-05-11 | Messer Griesheim Gmbh | Mikropartikel enthaltendes Injektionsanästhesiemittel |
| JP4544551B2 (ja) * | 1999-07-28 | 2010-09-15 | 日本曹達株式会社 | トリ−ｏ−チモチド類を成分化合物とする分子化合物 |
| WO2002045721A1 (en) * | 2000-12-04 | 2002-06-13 | Uws Ventures Limited | Noble gas complexes |
| US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028253A1 (en) * | 1979-05-04 | 1981-05-13 | Rasor Associates, Inc. | Ultrasonic image enhancement |
| EP0224934A2 (en) * | 1985-12-05 | 1987-06-10 | Steven B. Feinstein | Contrast agent, process for its preparation and its use for ultrasonic imaging |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3637926C1 (de) * | 1986-11-05 | 1987-11-26 | Schering Ag | Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen |
-
1988
- 1988-08-23 DE DE3828905A patent/DE3828905A1/de not_active Ceased
-
1989
- 1989-08-18 ES ES89250016T patent/ES2042986T3/es not_active Expired - Lifetime
- 1989-08-18 IE IE268589A patent/IE65168B1/en not_active IP Right Cessation
- 1989-08-18 EP EP89250016A patent/EP0357163B1/de not_active Expired - Lifetime
- 1989-08-18 WO PCT/DE1989/000548 patent/WO1990001952A1/de unknown
- 1989-08-18 AU AU40651/89A patent/AU641363B2/en not_active Ceased
- 1989-08-18 JP JP01508694A patent/JP3142539B2/ja not_active Expired - Fee Related
- 1989-08-18 AT AT89250016T patent/ATE76758T1/de not_active IP Right Cessation
- 1989-08-18 DE DE8989250016T patent/DE58901585D1/de not_active Expired - Lifetime
- 1989-08-22 PT PT91501A patent/PT91501B/pt not_active IP Right Cessation
-
1991
- 1991-02-21 DK DK030391A patent/DK30391A/da not_active Application Discontinuation
- 1991-02-22 NO NO910711A patent/NO302101B1/no not_active IP Right Cessation
-
1992
- 1992-08-20 GR GR920401406T patent/GR3005457T3/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028253A1 (en) * | 1979-05-04 | 1981-05-13 | Rasor Associates, Inc. | Ultrasonic image enhancement |
| EP0224934A2 (en) * | 1985-12-05 | 1987-06-10 | Steven B. Feinstein | Contrast agent, process for its preparation and its use for ultrasonic imaging |
Cited By (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| US5935553A (en) | 1989-12-22 | 1999-08-10 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US6315981B1 (en) | 1989-12-22 | 2001-11-13 | Imarx Therapeutics, Inc. | Gas filled microspheres as magnetic resonance imaging contrast agents |
| US6461586B1 (en) | 1989-12-22 | 2002-10-08 | Imarx Therapeutics, Inc. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5853752A (en) | 1989-12-22 | 1998-12-29 | Imarx Pharmaceutical Corp. | Methods of preparing gas and gaseous precursor-filled microspheres |
| US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
| US6033646A (en) | 1989-12-22 | 2000-03-07 | Imarx Pharmaceutical Corp. | Method of preparing fluorinated gas microspheres |
| US5985246A (en) | 1989-12-22 | 1999-11-16 | Imarx Pharmaceutical Corp. | Contrast agents for ultrasonic imaging and methods for preparing the same |
| US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
| US7078015B2 (en) | 1989-12-22 | 2006-07-18 | Imarx Therapeutics, Inc. | Ultrasound imaging and treatment |
| US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
| US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
| US6479034B1 (en) | 1989-12-22 | 2002-11-12 | Bristol-Myers Squibb Medical Imaging, Inc. | Method of preparing gas and gaseous precursor-filled microspheres |
| US6071495A (en) | 1989-12-22 | 2000-06-06 | Imarx Pharmaceutical Corp. | Targeted gas and gaseous precursor-filled liposomes |
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5770222A (en) | 1989-12-22 | 1998-06-23 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
| US6443898B1 (en) | 1989-12-22 | 2002-09-03 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems |
| US6773696B2 (en) | 1991-04-05 | 2004-08-10 | Bristol-Myers Squibb Medical Imaging, Inc. | Contrast agent comprising low density microspheres |
| US6528039B2 (en) | 1991-04-05 | 2003-03-04 | Bristol-Myers Squibb Medical Imaging, Inc. | Low density microspheres and their use as contrast agents for computed tomography and in other applications |
| US6117414A (en) | 1991-04-05 | 2000-09-12 | Imarx Pharmaceutical Corp. | Method of computed tomography using fluorinated gas-filled lipid microspheres as contract agents |
| US6998107B2 (en) | 1991-04-05 | 2006-02-14 | Bristol-Myers Squibb Pharma Comapany | Composition comprising low density microspheres |
| US7344705B2 (en) | 1991-04-05 | 2008-03-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Composition comprising low density microspheres |
| US7083572B2 (en) | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| US6576220B2 (en) | 1994-03-11 | 2003-06-10 | Imarx Therapeutics, Inc. | Non-invasive methods for surgery in the vasculature |
| US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| US7612033B2 (en) | 1994-11-29 | 2009-11-03 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| US6056938A (en) | 1995-02-21 | 2000-05-02 | Imarx Pharaceutical Corp. | Cationic lipids and the use thereof |
| US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
| US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
| US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
| US7329402B2 (en) | 1995-06-07 | 2008-02-12 | Imarx Pharmaceutical Corp. | Methods of imaging and treatment |
| US6638767B2 (en) | 1996-05-01 | 2003-10-28 | Imarx Pharmaceutical Corporation | Methods for delivering compounds into a cell |
| US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
| US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
| US6884407B1 (en) | 1996-09-11 | 2005-04-26 | Bristol-Myers Squibb Pharma Company | Methods for diagnostic imaging involving the use of a contrast agent and a coronary vasodilator |
| US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6403056B1 (en) | 1997-03-21 | 2002-06-11 | Imarx Therapeutics, Inc. | Method for delivering bioactive agents using cochleates |
| US6808720B2 (en) | 1997-03-21 | 2004-10-26 | Imarx Therapeutics, Inc. | Charged lipids and uses for the same |
| US6444660B1 (en) | 1997-05-06 | 2002-09-03 | Imarx Therapeutics, Inc. | Lipid soluble steroid prodrugs |
| US6028066A (en) | 1997-05-06 | 2000-02-22 | Imarx Pharmaceutical Corp. | Prodrugs comprising fluorinated amphiphiles |
| US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
| US7105151B2 (en) | 1997-06-18 | 2006-09-12 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
| US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
| US8658205B2 (en) | 1998-01-14 | 2014-02-25 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| US8084056B2 (en) | 1998-01-14 | 2011-12-27 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| US8685441B2 (en) | 1998-01-14 | 2014-04-01 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| US8747892B2 (en) | 1998-01-14 | 2014-06-10 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| US9545457B2 (en) | 1998-01-14 | 2017-01-17 | Lantheus Medical Imaging, Inc. | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| US7452551B1 (en) | 2000-10-30 | 2008-11-18 | Imarx Therapeutics, Inc. | Targeted compositions for diagnostic and therapeutic use |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3142539B2 (ja) | 2001-03-07 |
| EP0357163A1 (de) | 1990-03-07 |
| NO302101B1 (no) | 1998-01-26 |
| GR3005457T3 (enrdf_load_html_response) | 1993-05-24 |
| JPH04501559A (ja) | 1992-03-19 |
| AU4065189A (en) | 1990-03-23 |
| EP0357163B1 (de) | 1992-06-03 |
| ES2042986T3 (es) | 1993-12-16 |
| WO1990001952A1 (de) | 1990-03-08 |
| NO910711D0 (no) | 1991-02-22 |
| DE3828905A1 (de) | 1990-03-15 |
| IE892685L (en) | 1990-02-23 |
| ATE76758T1 (de) | 1992-06-15 |
| DK30391D0 (da) | 1991-02-21 |
| IE65168B1 (en) | 1995-10-04 |
| PT91501B (pt) | 1995-05-31 |
| NO910711L (no) | 1991-02-22 |
| PT91501A (pt) | 1990-03-08 |
| DK30391A (da) | 1991-02-21 |
| DE58901585D1 (de) | 1992-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU641363B2 (en) | Contrast preparation consisting of cavitate- or clathrate- forming host/guest complexes | |
| US5730954A (en) | Preparation comprising cavitate- or clathrate-forming host/guest complexes as contrast agent | |
| EP1742669B1 (en) | Compositions and methods for enhancing contrast in imaging | |
| US5141739A (en) | Delivery of x-ray contrast agents using receptor mediated endocytosis | |
| AU627456B2 (en) | Ultrasonic contrast medium made up of small gas bubbles and fatty-acid-containing microparticles | |
| EP0361894B1 (en) | Loading and controlled release of amphiphatic molecules to and from liposomes | |
| US6627749B1 (en) | Powdered oxidized cellulose | |
| MXPA01010752A (es) | Micelas polimericas hiper-ramificadas para encapsulacion y suministro de moleculas hidrofobas. | |
| EP1794192B1 (en) | Photoreactive polysaccharide, photocrosslinked polysaccharide products, the method of making them and medical materials made therefrom | |
| EP0586875A1 (de) | Ultraschallkontrastmittel, Verfahren zu deren Herstellung und deren Verwendung als Diagnostika und Therapeutika | |
| CA2219528A1 (en) | Stabilized compositions of fluorinated amphiphiles as contrast agents for ultrasound | |
| GB2041220A (en) | Medical preparations containing prostaglandins | |
| JPH01502270A (ja) | アンホテリシンｂ／硫酸コレステロール組成物およびその製造方法 | |
| US6858723B1 (en) | Amphiphile cyclodextrins, preparation and use thereof for solubilizing organized systems and incorporating hydrophobic molecules | |
| JP2003526637A (ja) | 非水性溶剤中の５−アミノレブリン酸製剤 | |
| US5750678A (en) | Water-soluble dextran fatty acid esters and their use as solubilizers | |
| KR20040065221A (ko) | 반응성 사이클로덱스트린의 제조방법, 상기사이클로덱스트린이 제공된 텍스타일 재료, 및 상기사이클로덱스트린 유도체의 용도 | |
| AU701797B2 (en) | Microparticles that contain gas, media that contain the latter, their use in ultrasonic diagnosis, as well as process for the production of the particles and media | |
| Tunik et al. | Synthesis and spectral characterization of new biodegradable arabinogalactan derivatives for diagnosis and therapy | |
| CN105348410B (zh) | 一种含碘多糖及其合成方法和应用 | |
| US5942501A (en) | Cyclodextrin derivative complex | |
| US20200237667A1 (en) | A biodegradable nano-theranostic composite and process of preparation thereof | |
| EP0273603A2 (en) | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside | |
| US6369037B1 (en) | Controlled release of doxorubicin | |
| CN113952290A (zh) | 一种纳米制剂水凝胶的制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |